GC Green Cross Develops 'RegulAItor' AI Chatbot for Pharmaceutical Regulatory Affairs
Supporting Regulatory Strategies Based on FDA Guidelines and Internal Approval Documents
GC Green Cross announced on June 5 that it has developed 'RegulAItor,' an AI-based in-house chatbot for Regulatory Affairs (RA) in pharmaceuticals. 'RegulAItor' is a chatbot that leverages AI technology to guide the direction of regulatory work, and it was developed to enhance the efficiency of regulatory strategy formulation and document review tasks for RA professionals.
'RegulAItor' utilizes the U.S. Food and Drug Administration (FDA) guidelines and GC Green Cross's internal approval documents as its dataset.
GC Green Cross's AI-based in-house Regulatory Affairs (RA) chatbot "RegulAItor" logo. GC Green Cross
View original imageBased on this, it analyzes approval modification categories and identifies similar approval cases and submission trends, enabling RA personnel to establish regulatory strategies more quickly and efficiently. Previously, staff had to spend hours manually reviewing extensive guidelines and internal documents to find the basis for approval changes, but with 'RegulAItor,' these tasks can be completed within 30 minutes.
Additionally, it operates in a secure internal data environment and is designed to generate responses only within its established dataset by applying Retrieval-Augmented Generation (RAG) technology. This blocks access to external data and minimizes the 'hallucination' phenomenon, a known limitation of generative AI, thereby increasing the reliability of the information provided.
GC Green Cross is the first in the domestic pharmaceutical industry to develop and deploy an AI chatbot specifically tailored for approval modification management in RA work. The company explained that it has recently completed trademark registration for the English name 'RegulAItor,' further solidifying its value as an independent, proprietary brand asset.
Jae-woo Lee, Head of Development at GC Green Cross, stated, "'RegulAItor' is meaningful in that it has systematized the approval experience and knowledge that were previously confined to specific departments into assets accessible by the entire organization. In particular, it is highly valuable that the know-how gained from successfully obtaining U.S. FDA approvals has been shared and internalized company-wide."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, GC Green Cross was previously selected as a core research institution for the Ministry of Science and ICT's project to 'establish and test a multi-agent AI platform for the entire cycle of AI-Medicine drug development.'
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.